It’s being expected that by 2030, the Anti-Fungal Drugs market cap will hit USD 14.8 billion at a CAGR growth of about 3.7 %.
Increasing occurrence of fungal infections like candidiasis and aspergillosis is the main factor boosting the growth of global anti-fungal drugs market. Antifungal products along with the fungicidal activity are used for treating diseases like ringworm, fungal meningitis and athlete’s foot caused by fungal agents. In addition, increase in the prevalence of the patients suffering from nosocomial infections or hospital acquired and infectious disease are supposed to encourage the growth of anti-fungal drugs market in the coming future.
Antifungal drugs are eliminating and detecting the fungal pathogens offering minimum side effect to the body. Fungal infection in the body is caused because of unclean and unhygienic environments where fungal infections are growing very well. Agents of fungal infection are getting multiplied by dispersing the spores that are moving towards the infection on skin or on inhaling. This infection of fungus is causing mucormycosis, fungal pneumonia, candidiasis and more.
Growth in the awareness related to myriad fungal infections, rise in the demand for drugs and increase in the occurrence of fungal infections are the factors responsible for the growth of global antifungal drugs market. Although, availability of the fake drugs towards the antifungal drugs are hampering the anti-fungal drugs market. Moreover, rise in the expenditure on the R&D activities related to the funding from the private and public sector is anticipated to offer various opportunities of growth to the antifungal drugs industry.
Increase in the knowledge about the infections of fungus and rise in the occurrence of fungal infections on the basis of infections of aggravating unhealthy environment in the coming years. Various antifungal drugs are available in the market for treating the dermal infections is positively impacting the growth of anti-fungal drugs market. Antifungal therapies are including drugs, ointments, pastes and powders is augmenting the antifungal drugs market growth.
Global antifungal drugs market trends are rising occurrence of the fungal infection is boosting the growth of antifungal drug market all over the world. Growth in the awareness is the main factor anticipating to encourage the antifungal drug market growth. In addition, compromised immune system and sedentary lifestyle are affecting the antifungal drug industry growth. Large use of conventional medication related to the traditional treatment is the main factor hindering the antifungal drug market growth. Continuous developments and research in evolving antifungal drugs are propelled to show the growth in the antifungal drugs market in terms of revenue over the forecast period.
Global antifungal drugs market is segmented into dosage forms, therapeutic indications, infection type, drug type and region. On considering the dosage forms, market is divided into drugs, ointments, powders and more. Based on therapeutic indications, market is divided into candidiasis, dermatophytosis, aspergillosis and more. On the basis of infection type, market is divided into systemic antifungal infections and superficial antifungal infections. Based on drug type, market is divided into allylamines, polyenes, azoles and echinocandins. Allylamines are further sub-divided into naftifine, terbinafine, butenafine and more whereas polyenes are divided into natamycin, hamycin, candicidin, amphotericin B and more. Azoles are divided into thiazoles, vornicanazole, imidazoles and more whereas echinocandins are divided into anidulafungin, micafungin, caspofungin and more.
Geographically, regions involved in the development of antifungal drugs market are Europe, North America, Latin America, Asia Pacific and Middle East & Africa. North America holds the largest global antifungal drugs market share. Asia Pacific is estimated to grow rapidly in the coming future.
Key players involved in the development of global antifungal drugs market are Sigma-Aldrich, Enzon Pharmaceuticals, Merck & Co, GlaxoSmithKline and Abbott.
Anti-Fungal Drugs Market Scope
|Forecast Unit||Value (USD)|
|Revenue forecast in 2030||USD 14.8 billion|
|Growth Rate||CAGR of 3.7% during 2020-2030|
|Segment Covered||Indication, Dosage Form, Regions|
|Regions Covered||North America, Europe, Asia Pacific, South America, Middle East and Africa|
|Key Players Profiled||F. Hoffmann-La Roche Ltd. (Switzerland), Mylan N.V. (US), Teva Pharmaceutical Industries Ltd.(Israel), Sanofi (France), Pfizer Inc. (US), GlaxoSmithKline plc (UK), Novartis AG (Switzerland), Sun Pharmaceutical Industries Ltd. (India), Gilead Sciences, Inc. (US), Apotex Inc. (Canada), Amneal Pharmaceuticals LLC. (US), Zydus Cadila (India), Aurobindo Pharma (India), Cipla Inc. (US), Hikma Pharmaceuticals PLC (UK), Dr. Reddy's Laboratories Ltd. (India), WOCKHARDT (India), Bausch Health Companies Inc. (Canada), Lannett (US), Torrent Pharmaceuticals Ltd. (India)|
Key Segments in the “Global Antifungal Drugs Market” are-
By Dosage Forms, market is segmented into:
By Therapeutic Indications, market is segmented into:
By Infection Type, market is segmented into:
- Systemic antifungal infections
- Superficial antifungal infections
By Drug Type, market is segmented into:
- Amphotericin B
By Regions market is segmented into:
- North America
- Latin America
- Asia Pacific
- Middle East & Africa